1. All-trans retinoic acid therapy for newly diagnosed acute promyelocytic leukemia: comparison with intensive chemotherapy

   • N. Asou
   • Koichi Adachi
   • and the Japan Adult Leukemia Study Group (JALSG)

   ORIGINAL ARTICLE Pages: S30 - S35

2. High-dose carboplatin plus paclitaxel with granulocyte colony-stimulating factor and peripheral blood stem-cell support in non-small-cell lung cancer

   • T. C. Shea

   ORIGINAL ARTICLE Pages: S74 - S78

3. Chemotherapy: the more the better? Overview

   • N. Saijo

   REVIEW Pages: S100 - S106

4. New concepts in the treatment of breast cancer using high-dose chemotherapy

   • William P. Peters
   • Roger Dansey

   ORIGINAL ARTICLE Pages: S88 - S93

5. Chemotherapy: the more, the better in malignant lymphoma?

   • K. Tobinai

   ORIGINAL ARTICLE Pages: S110 - S114

6. All-trans retinoic acid significantly increases 5-year survival in patients with acute promyelocytic leukemia: long-term follow-up of the New York study

   • Steven Soignet
   • Aaron Fleischauer
   • Raymond P. Warrell Jr.

   ORIGINAL ARTICLE Pages: S25 - S29

7. Treatment for adult T-cell leukemia

   • S. Hanada
   • Atae Utsunomiya
   • Terukatsu Arima

   ORIGINAL ARTICLE Pages: S47 - S50

8. New retinoids and arsenic compounds for the treatment of refractory acute promyelocytic leukemia: clinical and basic studies for the next generation

   • Kunio Kitamura
   • Hitoshi Kiyoi
   • Tomoki Naoe

   ORIGINAL ARTICLE Pages: S36 - S41

9. Importance of dose and dose intensity in the treatment of small-cell lung cancer

   • Nevin Murray

   REVIEW Pages: S58 - S63

10. Dose-intensive chemotherapy in extensive-stage small-cell lung cancer

    • S. Negoro
    • Noriyuki Masuda
    • Masahiro Fukuoka

    ORIGINAL ARTICLE Pages: S70 - S73

11. Chemotherapy for small-cell lung cancer: more is not better

    • H. Saka
    • Kaoru Shimokata

    ORIGINAL ARTICLE Pages: S107 - S109

12. High-dose chemotherapy with autologous hematopoietic stem-cell transplantation in breast cancer

    • Y. Tokuda
    • Masatoshi Ohta
    • Toshio Mitomi

    ORIGINAL ARTICLE Pages: S94 - S99

13. Pharmacological considerations in high-dose chemotherapy

    • Yasutsuna Sasaki

    ORIGINAL ARTICLE Pages: S115 - S118

14. Preface

    • H. Saito
    • Makoto Ogawa
    • Ryuzo Ohno

    ORIGINAL ARTICLE Pages: S1 - S2

15. Design and analysis of trials of salvage therapy in acute myelogenous leukemia

    • Elihu Estey
    • Peter Thall
    • Cynthia David

    ORIGINAL ARTICLE Pages: S9 - S12

16. New multidrug-resistance-reversing drugs, MS-209 and SDZ PSC 833

    • M. Naito
    • Takashi Tsuruo

    ORIGINAL ARTICLE Pages: S20 - S24

17. Cyclophosphamide, doxorubicin, vincristine, and prednisone versus intensive chemotherapy in non-Hodgkin’s lymphoma

    • R. I. Fisher

    ORIGINAL ARTICLE Pages: S42 - S46

18. Phase I/II trial of cure-oriented high-dose chemoradiotherapy with transplantation of CD34+ peripheral blood stem cells purified by the immunomagnetic bead method for refractory hematological malignancies

    • Michinori Ogura
    • Yoshitoyo Kagami
    • Nagoya CD34 Study Group

    ORIGINAL ARTICLE Pages: S51 - S57

19. Dose-intensive therapy in lung cancer

    • Anthony Elias

    ORIGINAL ARTICLE Pages: S64 - S69

20. Multidrug resistance: molecular mechanisms and clinical relevance

    • Victor Ling

    ORIGINAL ARTICLE Pages: S3 - S8

21. Modulation and prevention of multidrug resistance by inhibitors of P-glycoprotein

    • B. I. Sikic
    • George A. Fisher
    • Gang Chen

    ORIGINAL ARTICLE Pages: S13 - S19

22. High-dose chemotherapy with hematopoietic rescue in breast cancer: from theory to practice

    • W. R. Bezwoda

    ORIGINAL ARTICLE Pages: S79 - S87